Restasis has been in use in the United States for almost 20 years but until last week, a generic version was not available.
The FDA announced their approval of a generic form of cyclosporine ophthalmic emulsion (Viatris) 0.05% single use vials of eye drops.
In dry eye disease, it is common for the patient to have inadequate or unstable tear production. The cyclosporine drops are prescribed to help increase tear production in patients who are suffering from inflammation in their eyes due to dry eye.
The most commonly reported side effects of the drops were ocular burning, stinging and blurring of the eyes. The manufacturer hopes to bring Viatris to market very soon.